Camp4 Therapeutics Corp. (Ticker: CAMP) is a clinical-stage biopharmaceutical company focused on developing RNA-based therapeutics to upregulate gene expression for treating genetic diseases. Its lead product candidate, CMP-CPS-001, aims to be the first disease-modifying therapy for urea cycle disorders (UCDs), a group of severe metabolic diseases. The company is also advancing treatments for SYNGAP1-related disorders using its RAP platform.

Camp4 Therapeutics will list on October 11, 2024, on NASDAQ. The firm is offering 5 million shares at a price range of $14.00 to $16.00. The expected market capitalization at offer is $265.28 million. The total offer size is approximately $75 million. The offering is managed by J.P. Morgan, Leerink Partners, Piper Sandler, and William Blair.